Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs)

Abstract We tested the hypothesis that human tissue kallikreins (hKs) may regulate signal transduction by cleaving and activating proteinase-activated receptors (PARs). We found that hK5, 6 and 14 cleaved PAR N-terminal peptide sequences representing the cleavage/activation motifs of human PAR1 and PAR2 to yield receptor-activating peptides. hK5, 6 and 14 activated calcium signalling in rat PAR2-expressing (but not background) KNRK cells. Calcium signalling in HEK cells co-expressing human PAR1 and PAR2 was also triggered by hK14 (via PAR1 and PAR2) and hK6 (via PAR2). In isolated rat platelets that do not express PAR1, but signal via PAR4, hK14 also activated PAR-dependent calcium signalling responses and triggered aggregation. The aggregation response elicited by hK14 was in contrast to the lack of aggregation triggered by hK5 and 6. hK14 also caused vasorelaxation in a phenylephrine-preconstricted rat aorta ring assay and triggered oedema in an in vivo model of murine paw inflammation. We propose that, like thrombin and trypsin, the kallikreins must now be considered as important ‘hormonal’ regulators of tissue function, very likely acting in part via PARs.

[1]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[2]  Thomas A Luger,et al.  Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. , 2005, Endocrine reviews.

[3]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[4]  M. Hollenberg,et al.  Proteinase‐activated receptor‐4: evaluation of tethered ligand‐derived peptides as probes for receptor function and as inflammatory agonists in vivo , 2004, British journal of pharmacology.

[5]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[6]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[7]  N. Vergnolle Modulation of visceral pain and inflammation by protease‐activated receptors , 2004, British journal of pharmacology.

[8]  D. Katsaros,et al.  Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. , 2003, Cancer research.

[9]  M. Hollenberg,et al.  Proteinase-activated receptors in the nervous system , 2003, Nature Reviews Neuroscience.

[10]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[11]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[12]  J. Wallace,et al.  Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. , 2003, Canadian journal of physiology and pharmacology.

[13]  G. Yousef,et al.  Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. , 2003, Cancer research.

[14]  W. Ruf,et al.  Specificity of coagulation factor signaling , 2003, Journal of thrombosis and haemostasis : JTH.

[15]  M. Hollenberg,et al.  Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling. , 2002, The Biochemical journal.

[16]  J. Wallace,et al.  Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. , 2002, The American journal of pathology.

[17]  M. Hollenberg,et al.  Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta. , 2002, Canadian journal of physiology and pharmacology.

[18]  C. Lucchinetti,et al.  Activity of a newly identified serine protease in CNS demyelination. , 2002, Brain : a journal of neurology.

[19]  M. Hollenberg,et al.  International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors , 2002, Pharmacological Reviews.

[20]  M. Hollenberg,et al.  Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin. , 2002, The Journal of pharmacology and experimental therapeutics.

[21]  Moses Rodriguez,et al.  Enzymatic properties of rat myelencephalon-specific protease. , 2002, Biochemistry.

[22]  K. Fujikawa,et al.  Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. , 2001, Biochemistry.

[23]  A. Basbaum,et al.  Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway , 2001, Nature Medicine.

[24]  M. Hollenberg,et al.  Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. , 2001, Canadian journal of physiology and pharmacology.

[25]  D. Katsaros,et al.  Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer , 2001, British Journal of Cancer.

[26]  J. Wallace,et al.  Protease-activated receptors in inflammation, neuronal signaling and pain. , 2001, Trends in pharmacological sciences.

[27]  G. Yousef,et al.  Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. , 2000, Clinical biochemistry.

[28]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[29]  J. Wallace,et al.  Characterization of the inflammatory response to proteinase‐activated receptor‐2 (PAR2)‐activating peptides in the rat paw , 1999, British journal of pharmacology.

[30]  M. Hollenberg,et al.  Thrombin and mast cell tryptase regulate guinea‐pig myenteric neurons through proteinase‐activated receptors‐1 and −2 , 1999, The Journal of physiology.

[31]  J. Wallace,et al.  Pro‐ and anti‐inflammatory actions of thrombin: a distinct role for proteinase‐activated receptor‐1 (PAR1) , 1999, British journal of pharmacology.

[32]  K. Shigemasa,et al.  Increased Expression of Protease M in Ovarian Tumors , 1999, Tumor Biology.

[33]  J. Jesty,et al.  Mitogenic Responses Mediated Through the Proteinase-Activated Receptor-2 Are Induced by Expressed Forms of Mast Cell α- or β-Tryptases , 1997 .

[34]  M. Hollenberg,et al.  Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Hollenberg,et al.  Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. , 1997, Canadian journal of physiology and pharmacology.

[36]  C. Lazure,et al.  Prostatic kallikrein hK2, but not prostate‐specific antigen (hK3), activates single‐chain urokinase‐type plasminogen activator , 1997, International journal of cancer.

[37]  J. Hoxie,et al.  Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.

[38]  M. Hollenberg,et al.  Rat proteinase‐activated receptor‐2 (PAR‐2): cDNA sequence and activity of receptor‐derived peptides in gastric and vascular tissue , 1996, British journal of pharmacology.

[39]  M. Hollenberg,et al.  Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. , 1996, Molecular pharmacology.

[40]  M. Hollenberg,et al.  Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. , 1995, Canadian journal of physiology and pharmacology.

[41]  C. Wahlestedt,et al.  Molecular cloning of a potential proteinase activated receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Hollenberg,et al.  Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes. , 1993, Molecular pharmacology.

[43]  J. Pouysségur,et al.  cDNA cloning and expression of a hamster α‐thrombin receptor coupled to Ca2+ mobilization , 1991 .

[44]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[45]  M. Hollenberg,et al.  Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection , 2005 .

[46]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[47]  M. Hollenberg,et al.  Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. , 1999, The Journal of pharmacology and experimental therapeutics.

[48]  J. Jesty,et al.  Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell alpha- or beta-tryptases. , 1997, Blood.

[49]  J. Pouysségur,et al.  cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. , 1991, FEBS letters.